Menu
← Oncology Approval Tracker
FDA DECISION ·
Emrelis
telisotuzumab vedotin-tllv · AbbVie
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with previously systemically treated, locally advanced or metastatic nonsquamous NSCLC and high c-Met protein overexpression by an FDA-approved test (strong 3+ staining in at least 50% of tumor cells).
LAMPGEN ANALYSIS
Why it matters
This c-Met-directed antibody–drug conjugate is selected by protein expression, a different biomarker from MET exon 14 skipping.
What research teams should watch
Train pathology and screening teams on the exact staining threshold and collect the assay report rather than relying on a generic MET result.
PRIMARY RECORDS